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Abstract: In the human body, the central regulatory system of homeostasis is maintained by the
brain. Its complexity is mesmerizing and many of its functions are largely uncharted. Unfortunately,
its functionality is often impaired through neoplastic growths, like gliomas, which are devastating
to patients and their families. Annually, gliomas are the most common primary brain tumours
affecting over 20,000 people in the United States. However, despite their status as the third most
common cause of cancer related death for individuals between ages 20 and 39, the aetiology of
gliomas remains unknown. This paper aims to review the latest information regarding the 2016
World Health Organization (WHO) 4th edition classifications of gliomas, their malignant effects, and
disparities within these classifications, as well as identify areas for further research. These suggestions
for future inquiry may contribute to a better understanding of the pathology of these cancers enabling
improvement in prevention, screening, and treatment.
Keywords: cancer; brain tumour; tumour; gliomas; neurosurgery; neurology; brain

1. Introduction
Malignant brain tumours represent some of the most devastating diagnoses a clinician may ever
deliver to a patient. The most common malignant tumours of the brain are gliomas, accounting
for over 80% of all primary brain malignancies as demonstrated in Figure 1 [1]. These cancers are
aggressive, invasive, and destructive tumours, considered among the deadliest forms of human
cancers [2]. “Glioma” is a general term used to characterize any tumour that originates from glial
brain cells. There are three main cell types of glial origin with the potential to produce tumours.
These include astrocytes leading to astrocytomas (including glioblastomas), oligodendrocytes giving
rise to oligodendrogliomas, and ependymal cells forming ependymomas. Recent advances have
rendered this method of classification obsolete, and the World Health Organization (WHO) 2016 4th
edition classification standards include further separation of these subsections based on molecular and
genetic traits.
In the United States, nearly 10,000 cases of malignant gliomas are diagnosed annually, and merely
25% of such patients survive one year after diagnosis [3]. One of the main attributes of such a poor
prognosis is the lack of a standard treatment approach due to the heterogeneous nature of the tumours.
Current prognosis can be affected by several factors, including the patient’s health, age, the subtype of
glioma, and the location of the tumour within the brain [1,4]. Treatment is further complicated by the
fact that each tumour is unique in that they can represent multiple molecular phenotypes, requiring a
multi-modal approach to therapy [4]. After decades of scientific advances, aggregated data suggest
that the median survival range of 9–12 months for all gliomas has remained relatively unchanged
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Figure 1. Malignant primary brain tumours by histological morphology. Adapted with permission
from [1].
Figure 1. Malignant primary brain tumours by histological morphology. Adapted with permission
from [1].
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Nuclear Factor κB), though there are dozens more identified. Other non‐single gene modifications
include 1p/19q co‐deletions and RELA or BRAF fusion gene products. It is important to note that such
κB), though there are dozens more identified. Other non-single gene modifications include 1p/19q
mutations are acquired and not inherited. These mutations lead to dysregulation in DNA copying,
co-deletions and RELA or BRAF fusion gene products. It is important to note that such mutations
and growth causing cells to divide uncontrollably [8]. As previously discussed, with progression of
are acquired and not inherited. These mutations lead to dysregulation in DNA copying, and growth
discovery and detection methods, these mutations in neoplastic cells of glial origin have become
causing cells to divide uncontrollably [8]. As previously discussed, with progression of discovery and
critical in tumour classification, treatment, and prognosis [6].
detection methods, these mutations in neoplastic cells of glial origin have become critical in tumour
The development of a glioma is often accompanied by a myriad of symptoms which can
classification, treatment, and prognosis [6].
potentially affect any part of the central nervous system (CNS). Symptoms may include, but are not
The development of a glioma is often accompanied by a myriad of symptoms which can potentially
limited to headaches, seizures, visual changes, nausea, vomiting, vertigo, balance disturbances,
affect any part of the central nervous system (CNS). Symptoms may include, but are not limited to
hearing, gait, and postural instability. In other cases, patients may experience paralysis and
headaches, seizures, visual changes, nausea, vomiting, vertigo, balance disturbances, hearing, gait, and
paraesthesia of extremities, as well as respiratory arrest, coma, and death, if tumour development
postural instability. In other cases, patients may experience paralysis and paraesthesia of extremities,
causes cerebral herniation.
as well as respiratory arrest, coma, and death, if tumour development causes cerebral herniation.
Gliomas are classified by cell type, location, grade, and molecular markers according to the 2016
Gliomas are classified by cell type, location, grade, and molecular markers according to the 2016
WHO guidelines [9, 10]. Tumours are now classified based upon their histological and molecular or
WHO guidelines [9,10]. Tumours are now classified based upon their histological and molecular
genetic composition. For example, instead of the previous distinction as astrocytoma, these tumours
or genetic composition. For example, instead of the previous distinction as astrocytoma, these
may now be classified as a diffuse astrocytoma, IDH1/2 mutant, diffuse astrocytoma, IDH1/2 wild‐
tumours may now be classified as a diffuse astrocytoma, IDH1/2 mutant, diffuse astrocytoma, IDH1/2
type or diffuse astrocytoma, or NOS. In addition to describing these histological features in Section
wild-type or diffuse astrocytoma, or NOS. In addition to describing these histological features in
2, the function of these genetic and molecular alterations will be discussed in Section 3.
Section 2, the function of these genetic and molecular alterations will be discussed in Section 3.
Approximately 70% of gliomas in adults are supratentorial (above tentorium cerebelli), whereas 70%
Approximately 70% of gliomas in adults are supratentorial (above tentorium cerebelli), whereas 70% of
of the tumours in children are infratentorial (below tentorium cerebelli) [8]. Examples of the
the tumours in children are infratentorial (below tentorium cerebelli) [8]. Examples of the morphology
morphology of neuroglial cells are summarized in Figure 2 below.
of neuroglial cells are summarized in Figure 2 below.

Figure 2. Neuroglial morphologies. Reproduced from [11].
Figure 2. Neuroglial morphologies. Reproduced from [11].
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1.2. Diagnosis, Treatment, and Prognosis
1.2. Diagnosis, Treatment, and Prognosis
Patients, who present with symptoms of a glioma, are often first examined by a neurologist or a
Patients, who present with symptoms of a glioma, are often first examined by a neurologist or a
neurosurgeon. Imaging methods are used to visualize the brain tumour. Imaging techniques include
neurosurgeon. Imaging methods are used to visualize the brain tumour. Imaging techniques include
X‐ray, computed tomography (CT), or magnetic resonance imaging (MRI), amongst others. MRI
X-ray, computed tomography (CT), or magnetic resonance imaging (MRI), amongst others. MRI
typically provides the most detailed imaging of the brain, with the highest resolution. Confirmatory
typically provides the most detailed imaging of the brain, with the highest resolution. Confirmatory
diagnosis, classification, and grading require biopsy and evaluation by a pathologist, namely, a
diagnosis, classification, and grading require biopsy and evaluation by a pathologist, namely,
neuropathologist.
a neuropathologist.
Once diagnosed with a glioma, there are several options available to patients depending on their
Once diagnosed with a glioma, there are several options available to patients depending on their
desired outcome. Although each glioma subtype has distinct properties and requires a tumour‐
desired outcome. Although each glioma subtype has distinct properties and requires a tumour-specific
specific approach, nearly all treatments include some form of surgical resection. Some patients may
approach, nearly all treatments include some form of surgical resection. Some patients may choose to
choose to undergo a combination therapy, while others may forego treatment. Major factors
undergo a combination therapy, while others may forego treatment. Major factors influencing these
influencing these decisions are patient preferences, the anatomical location of the tumour, risks and
decisions are patient preferences, the anatomical location of the tumour, risks and benefits, prognosis
benefits, prognosis with versus without treatment, quality of life, and grade of the glioma amongst
with versus without treatment, quality of life, and grade of the glioma amongst others. Typically,
others. Typically, supportive therapy is provided to patients for immediate alleviation of symptoms.
supportive therapy is provided to patients for immediate alleviation of symptoms. Comprehensive
Comprehensive therapy applies multiple therapeutic modalities, including surgery, radiotherapy,
therapy applies multiple therapeutic modalities, including surgery, radiotherapy, and chemotherapy.
and chemotherapy. Surgery is typically highly invasive and attempts to resect as much of the tumour
Surgery is typically highly invasive and attempts to resect as much of the tumour as possible. However,
as possible. However, it should be noted that, in many instances, complete resection is not possible
it should be noted that, in many instances, complete resection is not possible due to the orientation
due to the orientation of vital nerves and blood vessels embedded within the tumour itself. Even if
of vital nerves and blood vessels embedded within the tumour itself. Even if the tumour can be
the tumour can be removed completely, there is a high tendency for regrowth [8]. Radiotherapy
removed completely, there is a high tendency for regrowth [8]. Radiotherapy provides an adjuvant
provides an adjuvant option, aiming to eradicate highly‐proliferative cells using an ionizing beam of
option, aiming to eradicate highly-proliferative cells using an ionizing beam of radiation directed at the
radiation directed at the tumour. Examples of such therapy include gamma therapy, Intensity
tumour. Examples of such therapy include gamma therapy, Intensity Modulated Radiation Therapy
Modulated Radiation Therapy (IMRT), Cyberknife™ (a robotic radiation therapy system from
(IMRT), Cyberknife™ (a robotic radiation therapy system from Accuray in Sunnyvale, CA, USA), and
Accuray in Sunnyvale, CA, USA), and stereotactic radiosurgery (SRS), among others. Further, a
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stereotactic radiosurgery (SRS), among others. Further, a combinational chemotherapy prescription is
given to patients to eradicate cancer cells by exploiting the various cancer cell irregularities.
Ultimately, about half of the patients in the United States who are diagnosed with malignant
gliomas of any classification are alive after one year, while roughly 25% are alive after two
years [8]. The devastating outcomes of these malignant tumours indicate the tremendous need
for improved treatment methods and critical research in prevention and enhanced understanding of
possible etiologist.
2. Biology of Gliomas
2.1. Physiology
Glioma stem cells are self-renewing populations of stem cells with enhanced tumorigenic
properties. These cells adopt many strategies to their advantage to rapidly propagate within the
brain. One of these properties includes increased stem cell propagation driven by both genetic and
epigenetic characteristics. Primarily, glioma cells reside in microenvironments that have limited
access to nutrients, like glucose and oxygen, which are necessary for cell survival. In such low
glucose conditions, glioma cells up-regulate GLUT3 (high-affinity neuronal glucose transporter type
3) [12]. Under hypoxic conditions, glioma cells preferentially utilize HIF-2α (hypoxia-inducible
factor) signalling for self-renewal, proliferation, and survival [13]. Glioma cells are also dependent
on NOS2 (nitric oxide synthase-2) activity for tumour growth. These cells synthesize nitric oxide
through the specific up-regulation of NOS2. Ultimately, this leads to the increased production of
nitric oxide allowing for maximum oxygen acquisition by the glioma cells [14]. Glioma cells also
express high amounts of VEGF (vascular endothelial growth factor) which is an important mediator
of angiogenesis [15]. Clinically, immune suppression is a hallmark of cancerous growth. These cells
produce a network of immunosuppressive pathways that disturb the effector function of immune cells
and reduce the efficacy of therapy aimed at reinforcing immune responses against glial tumours [16].
2.2. Morphology
Until recently, gliomas had been classified purely on their morphological and histological
features based upon the WHO first publishing of the Histological Typing of Tumours of the Central
Nervous System in 1979 [17]. Iterative editions were later published in 1993, 2007 [18,19] and,
most recently, in 2016 [9]. The WHO classification presented by Louis et al. primarily used
microscopy and immunohistochemistry tools to differentiate glioma subtypes [19]. Biopsy specimens
were categorized as astrocytomas, oligodendrogliomas, glioblastomas, or the catch-all category of
oligoastrocytomas. Astrocytomas are invasive tumours that do not form a solid mass or form clear
margins. Well-differentiated tumour cells exhibit a moderate increase in the number of nuclei,
variable nuclear pleomorphism, and a mesh-like network of glial fibrillary acidic protein (GFAP)
processes [20]. Well-differentiated astrocytomas may be identified using a GFAP immunohistochemical
stain. Oligodendrogilomas (grades 2/4) are diffuse tumours comprised primarily of sheets of cells
with spheroid nuclei surrounded by a clear halo of cytoplasm. Mitotic activity, nuclear anaplasia
and cell density increase with increasing WHO grade (2–4) [20]. Ependymomas are often more
circumscribed and less diffuse, arising from the ventricular floor. Upon biopsy, cells have regular
round or ovoid nuclei with a dense fibrillary background. As seen in Figures 4 and 5, ependymoma
cells often form canals or perivascular pseudorosettes, with tumour cells arranged surrounding central
blood vessels [20]. Less well differentiated tumours were historically difficult to accurately identify,
and determining astrocytic or oligodendrocytic cell lineage was a major challenge, leading to the
establishment of the oligoastrocytoma classification. Studies have shown that poorly-differentiated
tumour cells have high rates of inter-observer variability leading to misdiagnosis and inappropriate
clinical treatment [21]. With the advent of molecular genetic techniques and identification of key
prognostic markers, tumour classification is rapidly improving [9].
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Patients may present with headaches, seizures, memory loss or behavioural symptoms.
These cancers more frequently affect males over age 45. For all subtypes, surgery is the first
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procedure undertaken to remove the tumour, though regrowth after excision is a common observation.
Subsequent radiation may be used to target areas of incomplete removal [30].
3.1.2. Nitric Oxidase Synthase Mutation
NOS is a molecule that enhances vascular relaxation effects, macrophage and neutrophil
phagocytosis and cyclic guanosine monophosphate (GMP) production [34]. This factor is relevant in
the development of gliomas as it is a potent mediator of angiogenesis by stimulating VEGF production.
Studies have demonstrated that NOS is constitutively active in certain mutated astrocytomas. It has
been demonstrated that, at higher tumour grades, NOS is found at higher concentrations [35]. This is
to say; NOS mutation increases the likelihood that patients may develop gliomas through potentiation
of neovascularization and also attributes poorer prognosis for those afflicted with NOS mutated
tumours. Further, the dilatory effect of NOS allows for maximal oxygen uptake and utilization by
glioma cells [14]. The presence of NOS mutations is now used to further differentiate diffuse gliomas,
anaplastic astrocytomas, glioblastomas, oligodendrogliomas, oligoastrocytomas, and anaplastic
oligoastrocytomas [6]. As molecular technologies and targeted drug delivery models are developed,
this molecular alteration may become one possible means of treating and eliminating tumours of
glial origin.
3.1.3. H3-K27M Mutation and Diffuse Midline Gliomas
Diffuse midline gliomas (DMGs), are highly malignant midline gliomas that are primarily of
astrocytic differentiation. In a 2012 study, it was shown that two somatic mutations of the H3F3A and
HIST1H3B genes of histone H3, encoding the H3.1 and H3.3 histone variants are seen in paediatric
diffuse intrinsic pontine gliomas (DIPG) and non-brain stem gliomas [36–38]. Of particular note, the
K27M mutation (K-lysine to M-methionine at amino acid 27) was present in many H3 variants of both
DIPG and thalamic glioblastomas. Further research reveals that the H3-K27M mutation is present
in a majority of high-grade infiltrative astrocytomas arising within midline structures (thalamus,
pons, spinal cord) in both paediatric and adult cases [38]. Comparatively, a G34R/V (G-glycine to
R-arginine/V-valine at amino acid 34) was detected in a minor subset of peripheral glioblastomas
in the cerebral hemispheres. Clinical studies have shown that DIPGs with H3-K27 mutations are
associated with an aggressive clinical behaviour and poor prognosis regardless of histological grade,
thus, assigned a grade IV designation in the WHO 2016 4th Edition Classification [38–42].
3.1.4. 1p/19q Co-Deletion
Oligodendrogliomas are tumours arising from oligodendrocytes. The typical function of
oligodendrocytes is to form myelin in the central nervous system [43]. The 1p/19q co-deletion is one of
the best documented genetic markers for gliomas and is required to be deemed an oligodendroglioma
(anaplastic or typical) [9]. Oligodendrogliomas tend to be a glioma category with some of the best
outcomes and highest survival rates [24]. As shown in Figure 7, these tumours are soft and often
contain calcifications with small areas of haemorrhage or cyst development. This type of tumour is
most common in adult males between ages 35 and 44. They are rarely seen in paediatric populations,
accounting for only three percent of primary brain tumours [44]. These tumours may cause seizures,
headaches, personality changes, unilateral muscle weakness, or difficulty with short-term memory.
Factors that may increase the risk of oligodendroglioma include a family history of brain tumours,
history of epilepsy, and head trauma [45]. Surgical excision is the primary intervention in the treatment
of oligodendrogliomas. Subsequent chemotherapy may be adjuvant to surgery in anaplastic tumours,
mixed tumours, or those with 1p or 19q deletions. Since IDH mutant tumours tend to progress
more slowly, management is often less aggressive [46]. Similarly, depending on molecular markers
and grade, radiation may be indicated for treatment of oligodendroglioma. Favourable prognostic
indicators include frontal lobe location, low WHO grade, and combined 1p/19q loss [47].
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3.4. RELA
Recent amendments to the classification scheme for ependymomas rely on the presence of RELA
fusion positivity [6]. This mutation confers constitutive activation of NFκB (nuclear factor-κB) family
of transcriptional regulators. In this manner, these cells constantly act as mediators of the cellular
inflammatory response [64]. Though it is poorly understood how this mechanism precisely confers a
survival advantage to tumour cells, the presence of this mutation is confirmed in nearly two-thirds of
ependymomas [64]. This genetic alteration is detectable using FISH, making it readily measurable in
clinical practice. Further, the presence of RELA mutations is correlated with the expression of L-1 cell
adhesion molecules (CAM). RELA is not necessarily ependymoma-specific, but may guide treatment
in the future as novel molecular and gene targeted therapies are developed [64].
3.5. Other Gliomas
A few very rare glial cell tumours lack any differentiating mutations and are described
primarily on histologic and phenotypic features. These tumour types include angiocentric gliomas,
astroblastomas, and chordoid gliomas of the third ventricle [9]. Angiocentric gliomas are quite rare,
with less than 100 described in the literature through 2016 [65]. They are described as slow-growing,
supratentorial tumours that are often accompanied by seizures [66]. Treatment primarily consists
of resection and is curative, although given the low incidence of this tumour type approaches
often vary. Astroblastomas are another rare tumour that occurs primarily in children with seizures.
More commonly occurring in females, they tend to recur frequently with surgical resection being the
most common treatment approach [67]. Chordoid gliomas of the third ventricle typically occur around
age 50 and have an indolent course. Their location, however, frequently lies in close proximity to
the hypothalamus making even their slow-growth dangerous, often requiring surgical resection—a
delicate procedure [68].
3.6. Neuronal and Mixed Neuronal Glial Tumours
Another major alteration to the WHO guidelines for the classification of brain tumours, include
two lesions: diffuse leptomeningial glioneuronal tumours (DLGNT) and multinodular and vacuolating
neuronal tumours (MVNT). According to Komori [6], DLGNT tumours include characteristic
involvement of the leptomeninges of the spinal cord with or without parenchymal invasion [6].
These tumours include a dominant oligodendroglia-like cell mass and often possess BRAF fusions and
chromosome 1p deletions [6]. Comparatively, MVNT tumours possess multiple nodules composed
of vacuolating dysplastic neurons in the subcortical white matter. Hamartomatous MVNTs include a
distinctive nodular or ribbon-like growth pattern [6].
4. Trends in Gliomas in the United States
4.1. Racial Trends in the United States
The incidence of brain cancer has steadily increased for the last three decades, but has begun
gradually trending downwards in recent years. However, the diagnosis of glioblastoma is rising.
Given its poor survivorship, this trend is particularly concerning. Evaluation of data from 1973 to
2001 suggests that the most vulnerable demographic for the diagnosis of any brain cancer are white,
elderly white men residing in a metropolitan area, as depicted in Figure 10, although comprehensive
studies are limited [69]. Regarding glial cancers, data from 1992 through 2007 suggests significant
findings regarding race and the diagnosis of glioblastoma versus other glial brain cancer. In the United
States, Blacks, Asian/Pacific Islanders, and American Indians exhibit substantially lower rates of both
diagnoses. However, the variation in this rate was less dramatic in non-glioblastoma glial cancers than
glioblastoma [69].
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5. Conclusions and Future Work
In this paper, an overall evaluation and summary of currently available knowledge regarding
gliomas has been made to include the most common clinical presentations, known molecular
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5. Conclusions and Future Work
In this paper, an overall evaluation and summary of currently available knowledge regarding
gliomas has been made to include the most common clinical presentations, known molecular pathology,
diagnostic imaging, social demographics, physiology, as well as gross pathology and histology. Despite
having a general understanding of evident pathological gliomas, this knowledge represents only a
fraction of information yet to be determined. The continued poor prognosis for patients despite
the best available treatments and detection methods elucidates the need for a substantial amount of
work needed to enhance earlier detection and therapies to improve long-term prognosis. The current
trends in research are now focused on addressing these needs, and one of the most promising research
sectors dually serving to accomplish these objectives lies within molecular pathology. In addition,
brain tumour development is a very complex process and cannot be overly simplified. However,
current physiological models do not provide a clear algorithmic mechanism by which these cancers
develop. Part of this complexity lies within the multifactorial nature of these proliferations and
the undetermined cellular pathophysiology. By coupling further epidemiological investigation with
continued basic science exploration, it is promising that a discovery of the possible aetiologies can be
made with a high degree of sensitivity and specificity. This may drastically improve the timeliness of
diagnosis and the long-term prognosis for those who develop tumours.
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